Verrica Pharmaceuticals Inc Aktie News

– Die per-Protokoll Zwischenanalyse der statistischen Power bestätigt, dass keine zusätzlichen Patienten für die vollständige Einschreibung empfohlen werden – – Die zweite zulassungsrelevante Phase-3-Studie (COVE-3) hat bereits mehr als 50 % der aktuellen Ziel-Einschreibung überschritten; Topline-Daten werden derzeit für Mitte 2027 erwartet – WEST CHESTER, Pa., 27. Aug. 2026 (GLOBE NEWSWIRE) --...

WEST CHESTER, Pa., 21. Juli 2026 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. („Verrica“) (Nasdaq: VRCA), ein Therapeutika-Unternehmen, das Medikamente zur Behandlung dermatologischer Erkrankungen einschließlich Hautkrebs entwickelt und vermarktet, gab heute einen exklusiven Vertriebs-, Marketing- und Liefervertrag („die Vereinbarung“) bekannt, der Medomie Pharma Ltd. entsprechende Rechte g...

– Development Partner Torii Pharmaceutical also recently announced dosing of the first Japanese patient in this trial evaluating YCANTH (TO-208) in Japan –

WEST CHESTER, Pa., May 28, 2026 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica”) (Nasdaq: VRCA), a therapeutics company developing and commercializing medications for the treatment of dermatological diseases, including skin cancers, today announced that Jayson Rieger, PhD, MBA, President and Chief Executive Officer of Verrica Pharmaceuticals, will present at the Jefferies Global Hea...

WEST CHESTER, Pa., May 13, 2026 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica”) (Nasdaq: VRCA), a therapeutics company developing and commercializing medications for the treatment of dermatological diseases, including skin cancers, today announced that Jayson Rieger, PhD, MBA, President and Chief Executive Officer of Verrica Pharmaceuticals, will present at the H.C. Wainwright 4th ...

Verrica Pharmaceuticals NASDAQ: VRCA reported higher first-quarter revenue and record demand for its molluscum contagiosum treatment YCANTH, while outlining progress on late-stage development programs in common warts and basal cell carcinoma.

– Company reports record demand for YCANTH® as dispensed applicator units grew to 15,302 in Q1 2026, up 12.1% over the previous quarter and 51.3% year-over-year, and has now exceeded 100,000 dispensed applicator units since launch – – Company announces achievement of over 50% of current targeted enrollment in the first trial in global Phase 3 common warts program and expects to initiate the sec...